Safety of high-dose of nafamostat mesilate: toxicological study in beagles.
نویسندگان
چکیده
The acute effects of a high dose of nafamostat mesilate (NM, 6-amidino-2-naphthyl-p-guanidinobenzoate dimethanesulfonate) were studied in 14 beagles (six controls). NM (10 mg kg-1 hr-1) was continuously administered intravenously for 24 hr. The activated coagulation time was dose-dependently prolonged with NM. Plasma electrolyte imbalances such as hyponatremia, hypochloremia, hyperkalemia and active excretion of sodium into urine were found. Aldosterone levels tended to increase in blood and urine after the administration of NM. Although the precise mechanism of these electrolyte imbalances remains unknown, the increase of aldosterone in blood and urine may have been a secondary response to, rather than the cause of, the electrolyte imbalances. Mean arterial pressure gradually decreased after 5 hr of NM. This hypotension may have reflected the vasodilatation with NM. Although the biochemical and histological studies did not reveal significant side effects, further study will be required to confirm the safety of long-term, high-dose NM. These results indicate that the high-dose NM administration at a rate of 10 mg kg-1 hr-1 during 24 hr has no serious side effects.
منابع مشابه
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
BACKGROUND The primary end points of this study were to determine the dose-limiting toxic effects (DLTs), maximum tolerated dose, and a recommended phase II dose of a synthetic serine protease inhibitor, nafamostat mesilate, in combination with full-dose gemcitabine in patients with unresectable locally advanced or metastatic pancreatic cancer. The secondary end point was to assess therapeutic ...
متن کاملEffects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
BACKGROUND The pharmacological inhibition of blood-foreign surface interactions is an attractive strategy for reducing the morbidity associated with cardiopulmonary bypass. We compared the inhibitory effects of nafamostat mesilate (a broad-spectrum synthetic protease inhibitor) and minimal-dose aprotinin on blood-surface interactions in clinical cardiopulmonary bypass. METHODS Eighteen patien...
متن کاملChanges in blood viscosity with synthetic protease inhibitors.
We examined the effects on whole blood viscosity and coagulation time of various dosages of the synthetic low-molecular protease inhibitors gabexate mesilate and nafamostat mesilate with an oscillation-type viscometer. When either agent was added, blood viscosity decreased dose-dependently along a sigmoid-like curve. Furthermore, coagulation time was shorter with gabexate mesilate than with naf...
متن کاملUse of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
Although the incidence of bleeding complications during extracorporeal membrane oxygenator (ECMO) support has decreased in various trials, bleeding is still the most fatal complication. We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure. We assessed 73 consecutive patients who received ECMO due to acute ca...
متن کاملAbility of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
UNLABELLED Continuous renal replacement therapy (CRRT) is considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care units (ICUs). However, the role of heparin anticoagulation, which is used to maintain circuit patency, is equivocal due to the risk of bleeding and morbidity. Among various alternative anticoagulants, nafamostat me...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of pharmacology and experimental therapeutics
دوره 268 2 شماره
صفحات -
تاریخ انتشار 1994